title: Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.
abstract: Bladder drug delivery via catheter instillation is a widely used treatment for recurrence of superficial bladder cancer. Intravesical instillation of liposomal botulinum toxin has recently shown promise in the treatment of overactive bladder and interstitial cystitis/bladder pain syndrome, and studies of liposomal tacrolimus instillations show promise in the treatment of hemorrhagic cystitis. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core that can encapsulate hydrophilic and hydrophobic drug molecules to be delivered to cells via endocytosis. This review will present new developments on instillations of liposomes and liposome-encapsulated drugs into the urinary bladder for treating lower urinary tract dysfunction.
authors.affiliation: Lipella Pharmaceuticals, Pittsburgh, PA 19019, USA. joe.janicki@lipella.com.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Janicki
authors.affiliation: Lipella Pharmaceuticals, Pittsburgh, PA 19019, USA. chancellormb@gmail.com.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Chancellor
authors.affiliation: Lipella Pharmaceuticals, Pittsburgh, PA 19019, USA. mdato@aol.com.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kaufman
authors.affiliation: Lipella Pharmaceuticals, Pittsburgh, PA 19019, USA. michele.anthony@lipella.com.
authors.forename: Michele A
authors.initials: MA
authors.lastname: Gruber
authors.affiliation: Lipella Pharmaceuticals, Pittsburgh, PA 19019, USA. daviddchancellor@gmail.com.
authors.forename: David D
authors.initials: DD
authors.lastname: Chancellor
mesh_terms: D000283:Administration, Intravesical; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008081:Liposomes; D009498:Neurotoxins / Q000008:administration & dosage* / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019459:Urothelium / Q000378:metabolism / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D008081:Liposomes; D009498:Neurotoxins; D019274:Botulinum Toxins, Type A; D016559:Tacrolimus
keywords: bladder; botulinum toxin; interstitial cystitis; liposome; overactive bladder